Nuclear Grade is Critical for Prognosis in Pediatric Clear Cell RCC
Nuclear grading using the WHO/ISUP system remains one of the most important prognostic factors for clear cell renal cell carcinoma, including in pediatric cases, and should be routinely reported on all histopathology specimens. 1
Key Prognostic Role
The WHO/ISUP nuclear grade is established as a key prognostic feature for clear cell RCC alongside TNM stage, coagulative necrosis, and presence of rhabdoid/sarcomatoid differentiation 1. This grading system is based primarily on nucleolar prominence rather than nuclear size or shape, which has been validated as the most reproducible and prognostically significant component 2.
The Four-Tier Grading System
The WHO/ISUP grading divides tumors into four grades based on nucleolar prominence:
- Grade 1: Inconspicuous nucleoli at 400x magnification
- Grade 2: Visible nucleoli at 400x magnification
- Grade 3: Prominent nucleoli at 100x magnification
- Grade 4: Extreme nuclear pleomorphism, sarcomatoid features, or rhabdoid differentiation
Clinical Significance Across All Stages
Nuclear grade demonstrates prognostic value even in early-stage disease. High nuclear grade (grades 3-4) is an independent risk factor for tumor recurrence and metastasis, even in pathologic T1a tumors (≤4 cm) 3. Patients with high-grade T1a tumors showed only 67.8% 5-year recurrence-free survival compared to 96.8% for low-grade tumors 3.
Enhanced Prognostic Value with Necrosis
Tumor necrosis adds significant prognostic information to nuclear grade alone 4, 5. When necrosis is incorporated into grading, patients can be stratified into distinct prognostic groups:
- Non-necrotic ISUP grades 1-3 tumors (best prognosis)
- ISUP grades 1-3 with necrosis or grade 4 with <10% necrosis (intermediate)
- ISUP grade 4 with >10% necrosis (worst prognosis) 4
Pediatric Considerations
While the provided evidence focuses primarily on adult populations, the same grading principles apply to pediatric clear cell RCC 1. The GUPS guidelines make no distinction in grading methodology between adult and pediatric cases, indicating universal applicability of the WHO/ISUP system.
Important Caveats for Pediatric Cases
- Consider hereditary syndromes (VHL disease) in pediatric presentations, which may present with bilateral or multifocal tumors 6
- Maintain a low threshold for additional immunohistochemistry (FH, 2SC, SDHB) in younger patients with difficult-to-classify tumors, particularly those with eosinophilic morphology 1
- Current evidence does not support a unique tumor subtype occurring after chemotherapy/radiation in early childhood 1
Practical Reporting Requirements
Every clear cell RCC pathology report should include:
- WHO/ISUP nuclear grade (1-4) based on worst area
- Presence and extent of coagulative necrosis
- TNM stage
- Presence of sarcomatoid or rhabdoid differentiation
- Molecular findings when available (VHL status, SETD2, PBRM1, BAP1) 1
The combination of these factors provides the most accurate prognostic stratification and guides treatment decisions, including consideration of immunotherapeutic agents in advanced disease 1.